GSPT1 protein degrader containing oxime structure, and preparation method therefor and use thereof

By developing GSPT1 protein degrading agents containing oxime structures, especially compounds OX-7 and NX-7, the degradation of GSPT1 protein and the anti-proliferation inhibitory activity of AML cells has been significantly improved, and existing drugs have been solved in the treatment of acute myeloid leukemia. The shortcomings in the process broaden the indications for tumor treatment.

WO2024251301A1PCT designated stage expired Publication Date: 2024-12-12CHINA PHARM UNIV

Patent Information

Application Number
PCT/CN2024/103853
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-06
Filing Date
2024-07-05
Publication Date
2024-12-12

AI Technical Summary

Technical Problem

The existing GSPT1 protein degrading agents have certain limitations in the treatment of acute myeloid leukemia and other tumors, especially in the degradation effect and anti-proliferative inhibitory activity of GSPT1, which has not yet achieved the best effect, and its application in different tumor types The mechanism has not been studied in depth.

Method used

A GSPT1 protein degrading agent containing oxime structure was developed. By optimizing the compound structure, the degradation activity against GSPT1 was improved, and specific compounds such as OX-7 and NX-7 were provided through the synthetic route, which significantly improved the AML cells' Antiproliferative inhibitory activity and broaden the scope of tumor indications.

Benefits of technology

The compounds OX-7 and NX-7 degraded GSPT1 protein in KG-1 cells more than 80%, and showed significant anti-proliferation inhibitory activity in different tumor cells. The IC50 value is in the range of 1-10 nM, which is better than Clinical drug CC-90009, and the degradation effect is concentration and time-dependent.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024103853_12122024_PF_FP_ABST
    Figure CN2024103853_12122024_PF_FP_ABST
Patent Text Reader

Abstract

A GSPT1 protein degrader containing an oxime structure, and a preparation method therefor and the use thereof. Disclosed in the present invention is a compound containing an oxime structure or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer or diastereomer thereof. The compound of the present invention has excellent GSPT1 degradation activity, and can be used as a GSPT1 protein degrader, which broadens the skeleton structure of the GSPT1 molecular glue degrader, improves an anti-proliferation effect on tumors, improves the therapeutic window, and provides more choices for the research and development of GSPT1 molecular glue. Compared with the clinical drug CC-90009, the oxime compounds, such as OX, NX and CX series, of the present invention have significantly improved degradation effects on GSPT1 protein and significantly improved anti-proliferation and inhibitory activity on AML cells.
Need to check novelty before this filing date? Find Prior Art

Description

A GSPT1 protein degrader containing an oxime structure, and its preparation method and application Technical Field

[0001] The present invention belongs to the technical field of chemical medicine, and in particular relates to a GSPT1 protein degradation agent containing an oxime structure, a preparation method and an application thereof. Background Art

[0002] Targeted protein degradation technology (TPD) is a new technology that interferes with protein function by utilizing the protein degradation mechanism inherent in eukaryotic cells that regulates protein homeostasis. The rise of this technology has, to a certain extent, solved the difficulties faced by small molecule inhibitors and gene interference technologies. TPD currently mainly degrades target proteins through ubiquitin proteasomes and lysosomes. Currently, the most mature and most studied in this field are proteolysis-targeting chimeras (PROTACs) and molecular glues (MGs) based on the ubiquitination-proteasome system. Targeted protein degradation technology has broad application prospects and development space in a variety of disease areas, such as malignant tumors, neurodegenerative diseases, metabolic diseases and other fields.

[0003] Molecular glues are small molecules that induce proximity and enable precise temporal control of various biological processes, such as signal transduction, transcription, chromatin regulation, and protein folding, localization, and degradation. As chemical inducers of proximity, they can induce protein-protein interactions between E3 ubiquitin ligases and target proteins, leading to their degradation. Molecular glues can promote dimerization or colocalization of two proteins by forming ternary complexes, resulting in a variety of biological and pharmacological functions.

[0004] G1 to S phase transition 1 (GSPT1, also known as eRF3a) is a translation termination factor in vivo. Downregulation of GSPT1 can lead to aberrant expression of key proteins, inhibiting proliferation or inducing apoptosis in various tumor cells. Since the discovery of GSPT1 as a novel substrate of the E3 ubiquitin ligase CRBN, it has become a target for targeted degradation by molecular adhesive degraders. Currently, a variety of molecular adhesive degraders are in clinical and preclinical development, and these molecules are highly effective in treating hematologic malignancies and certain solid tumors. GSPT1 possesses multifunctional properties. In addition to acting as a second peptide chain release factor, involved in protein translation termination, it is also implicated in apoptosis, cell cycle regulation, and tumor development and progression. For example, during apoptosis, GSPT1 is proteolytically processed to form another isoform that contains a conserved N-terminal inhibitor of apoptosis protein binding domain. GSPT1 interacts with inhibitors of apoptosis proteins (IAPs) through this processed form, releasing the inhibition of IAPs and releasing caspases, thereby promoting cell apoptosis. The M domain of eRF3 interacts with Polya-binding protein (PABP), coupling translation termination and mRNA degradation.

[0005] CC-885, a 5-substituted isoindoline compound, has strong CRBN-dependent antiproliferative activity in a wide range of tumor cell lines, with enhanced antiproliferative activity compared to lenalidomide and pomalidomide (Nature 2016, 535, 252-257). Immunoprecipitation and immunoblotting assays showed that CC-885 promoted the binding of CRBN to the novel substrate GSPT1, targeting its degradation. Using CC-885 as a structural template, a difluoroacetamide skeleton was discovered through SAR, which showed good selectivity in vitro (J. Med. Chem. 2021, 64, 1835-1843). Based on this, BMS / Celgene's third-generation lead compound CC-90009 was further screened. CC-90009 is a highly effective GSPT1 selective degrader that has demonstrated good PK / PD and safety in the treatment of acute myeloid leukemia and has entered Phase I / II clinical trials (NCT04297124; NCT02848001; NCT04336982).

[0006] Acute myeloid leukemia (AML) is a genetically and biologically heterogeneous myeloid malignancy characterized by the abnormal expansion of immature myeloid progenitor cells, which impairs normal hematopoiesis, leading to severe infections, anemia, and bleeding. It is characterized by low survival and high relapse rates. As a relatively rare malignancy, it has been designated an orphan disease by the US Food and Drug Administration. GSPT1, a novel substrate of the CRL4-CRBN-E3 ubiquitin ligase, plays a key role in the treatment of AML. Clinical drugs targeting GSPT1 for the treatment of AML, such as CC-90009 and BTX-1188, are under development. CC-90009 is primarily administered intravenously for the treatment of AML, while BTX-1188 is an oral drug used to treat AML and NHL. Further research has revealed that GSPT1 degradation is associated with upregulation of ATF3 and ATF4 gene expression, which are crucial for the integrated stress response pathway. The activation of the integrated stress response pathway is closely related to the phosphorylation of eRF2. When the integrated stress response pathway is activated, it will lead to acute cell apoptosis.

[0007] In summary, GSPT1 plays a crucial role in the development and progression of solid tumors. However, due to its diverse functions and complex regulatory mechanisms, it plays distinct roles in different tumors. It is generally accepted that GSPT1 is a proto-oncogene in most tumors and, in certain specific tumor types, acts as a tumor suppressor gene. While the mechanisms of GSPT1's action in tumors remain understudied, there is no doubt that GSPT1 has become a promising potential target for cancer treatment.

[0008] Summary of the Invention

[0009] Purpose of the Invention: The present invention aims to provide an oxime-containing GSPT1 protein degrader, its preparation method, and application. The oxime-containing compound of the present invention exhibits excellent GSPT1 degradation activity and can be used as a GSPT1 protein degrader. This broadens the framework of GSPT1 molecular glue degraders, enhances their anti-tumor proliferative effects, improves the therapeutic window, and provides more options for the research and development of GSPT1 molecular glues.

[0010] Technical solution: The purpose of the present invention is achieved through the following technical solution:

[0011] The present invention provides a compound represented by general formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, or diastereomer thereof:

[0012] in:

[0013] X is selected from -OH, -NH2, -OCH3 or -NHCOCH3;

[0014] Ring Y is selected from C6-C 12 Aryl, 5-10 membered heteroaryl, C3-C8 cycloalkyl or 3-10 membered heterocyclyl, said aryl, heteroaryl, cycloalkyl and heterocyclyl being unsubstituted or optionally substituted by 1-3 R a replace;

[0015] R1 is selected from

[0016] R2 is selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2R a or 3-10 membered cycloalkyl, heterocyclyl, aryl and heteroaryl containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are unsubstituted or optionally substituted with 1-3 R a replace;

[0017] Each R3 is independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2R aor 3-10 membered cycloalkyl, heterocyclyl, aryl and heteroaryl containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are unsubstituted or optionally substituted with 1-3 R a replace;

[0018] R4 is selected from hydrogen, deuterium, halogen or C1-C6 alkyl;

[0019] R5 is selected from hydrogen, deuterium, C1-C 12 alkyl,

[0020] Z is selected from -CH2-, -CD2-, -C(O)- or -C(S)-;

[0021] R6, R7, R8, R9, R 10 、R 11 are independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2R a or 3-10 membered cycloalkyl, heterocyclyl, aryl and heteroaryl containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are unsubstituted or optionally substituted with 1-3 R a replace;

[0022] Each R a 、R b are independently selected from hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, hydroxyl, cyano, nitro, benzyl, -C(O)NR c R d 、-C(O)R c 、-C(O)OR c 、-OR c 、-OC(O)R c 、-OC(O)OR c 、-OC(O)NR c R d 、-NRc R d 、-SR c 、-S(O)R c 、-S(O)2R c or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group is unsubstituted or optionally substituted with 1-3 R c replace;

[0023] Each R c 、R d Each is independently selected from hydrogen, halogen, carbonyl, hydroxyl, cyano, nitro, phenyl, benzyl, C1-C6 alkyl, halogenated C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C3-C6 cycloalkyl or halogenated C3-C6 cycloalkyl;

[0024] m, n, and p are each independently selected from 0, 1, 2, or 3.

[0025] The compound of the general formula I of the present invention or its pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer, preferably a compound having the structure of formula Ia, formula Ib or formula Ic:

[0026] wherein X, Y, Z, m, n, and p are as defined in Formula I.

[0027] In certain preferred embodiments,

[0028] X is selected from -OH, -NH2 or -OCH3.

[0029] In certain preferred embodiments,

[0030] R2 is selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O)2R a ;

[0031] R a 、R b are independently selected from hydrogen, C1-C6 alkyl or -C(O)R c ;

[0032] R c is selected from hydrogen, halogen, C1-C6 alkyl, halo-C1-C6 alkyl, C1-C6 alkoxy, halo-C1-C6 alkoxy or C3-C6 cycloalkyl;

[0033] Ring Y is selected from C6-C 12 aryl or 5-10 membered heteroaryl.

[0034] In certain more preferred embodiments,

[0035] R3 is selected from hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halogen, cyano or nitro;

[0036] R4 is selected from hydrogen, deuterium, halogen or C1-C6 alkyl;

[0037] R5 is selected from hydrogen, deuterium or C1-C 12 alkyl;

[0038] m and n are each independently selected from 1;

[0039] p is selected from 0 or 1.

[0040] The compounds of the general formula I described above may also exist in the form of their salts, which are converted in vivo into compounds of the general formula I. For example, within the scope of the present invention, the compounds of the present invention may be converted into pharmaceutically acceptable salts according to processes known in the art and used in the form of salts.

[0041] In some preferred embodiments, the pharmaceutically acceptable salts include but are not limited to acid addition salts formed between the compound of formula I and the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, naphthalenesulfonic acid, citric acid, tartaric acid, lactic acid, pyruvic acid, acetic acid, maleic acid or succinic acid, fumaric acid, salicylic acid, phenylacetic acid, mandelic acid; and also include acid salts formed between the compound of formula I and inorganic bases.

[0042] In some more preferred embodiments, the pharmaceutically acceptable salts include, but are not limited to, basic metal cation salts, alkaline earth metal cation salts, and ammonium cation salts.

[0043] The compounds of the general formula I of the present invention are preferably the following compounds:

[0044] The present invention also provides a method for preparing compounds of Formula Ia, Ib, and Ic. The synthetic route is as follows:

[0045] The starting material 1 is brominated with N-bromosuccinimide in the presence of a free radical initiator to obtain intermediate 2; intermediate 2 is substituted with a nucleophile 3-aminopiperidine-2,6-dione hydrochloride and further formed into a lactam on the ester to obtain intermediate 3; a cyano group is inserted into the aryl bromide via palladium mediation to obtain intermediate 4; followed by reduction and de-tert-butyloxycarbonylation to obtain intermediate 6, and finally, in the presence of a condensing agent EDCI, to obtain compounds related to formulas Ia, Ib, and Ic.

[0046] Another object of the present invention is to provide a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer thereof, and a pharmaceutically acceptable carrier or excipient.

[0047] The pharmaceutical compositions of the present invention can be administered in various known ways, such as orally, parenterally, by inhalation spray, or via an implanted reservoir. The pharmaceutical compositions of the present invention can be administered alone or in combination with other drugs. Oral compositions can be in any orally acceptable dosage form, including but not limited to tablets, capsules, emulsions, suspensions, dispersions, and solutions. Commonly used pharmaceutically acceptable carriers or excipients include stabilizers, diluents, surfactants, lubricants, antioxidants, binders, colorants, fillers, emulsifiers, and the like.

[0048] Sterile injectable compositions can be formulated using suitable dispersing agents or wetting agents and suspending agents according to techniques known in the art. Pharmaceutically acceptable carriers and solvents that can be used include water, mannitol, sodium chloride solution, and the like.

[0049] Actual dosage levels of the active ingredients in the pharmaceutical compositions of the present invention may be varied to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, and mode of administration, without being toxic to the patient. The selected dosage level will depend upon a variety of factors, including the activity of the specific compound of the present invention or salt thereof employed, the route of administration, the time of administration, the rate of excretion of the specific composition employed, the duration of treatment, other drugs, compounds, and / or materials used in combination with the specific composition employed, the age, sex, weight, general health, and prior medical history of the patient being treated, and similar factors well known in the medical arts.

[0050] Another object of the present invention is to provide the use of a compound of formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, or diastereomer thereof in the preparation of a medicament for treating or preventing diseases associated with GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC, or C-MYC protein mutations, expression imbalances, allostery, and functional abnormalities.

[0051] The related diseases are cancer, viral infection, aging, immune diseases, and neurological diseases; wherein the cancer is selected from acute myeloid leukemia, liver cancer, acute lymphocytic leukemia, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, chronic lymphocytic leukemia CLL, chronic myeloid leukemia CML, colon cancer, esophageal cancer, gallbladder cancer, gastric cancer, gastrointestinal stromal tumor, head and neck cancer, Hodgkin's lymphoma, laryngeal cancer, leukemia, lung cancer, melanoma, mesothelioma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, kidney cancer, sarcoma, skin cancer, small cell lung cancer, testicular cancer, pharyngeal cancer, thyroid cancer or uterine cancer.

[0052] The present invention also provides use of a compound of formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, or diastereomer thereof in the preparation of a GSPT1 degrading agent.

[0053] The term "isomer" includes enantiomeric, diastereomeric, and geometric (or conformational) isomeric forms of a given structure. For example, the present application includes R and S configurations for each asymmetric center, Z and E double bond isomers, Z and E conformational isomers, single stereochemical isomers, and enantiomeric, diastereomeric, and geometric (or conformational) isomer mixtures.

[0054] The term "pharmaceutically acceptable salt" refers to, for example, acid addition salts and / or base salts thereof. Suitable acid addition salts are formed from acids that form non-toxic salts, such as hydrochlorides / chlorides. Suitable base salts are formed from bases that form non-toxic salts, such as calcium salts and sodium salts. Hemi-salts of acids and bases can also be formed, such as hemisulfate salts and hemicalcium salts.

[0055] The term "therapeutically effective amount" refers to an amount of a compound of the invention that (i) treats a specific disease, condition, or disorder; (ii) reduces, alleviates, or eliminates one or more symptoms of a specific disease, condition, or disorder; or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition, or disorder described herein.

[0056] The term "pharmaceutically acceptable carrier or excipient" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated therewith. Beneficial effects:

[0057] Compared to the clinical drug CC-90009, the oxime compounds of the present invention, such as the OX, NX, and CX series, demonstrate significantly enhanced GSPT1 protein degradation and anti-proliferative activity in AML cells. Specifically, OX-7, a 200 nM compound, exhibited over 80% GSPT1 protein degradation in KG-1 cells after 4 hours of administration. Under the same conditions, NX-7 also exhibited over 90% GSPT1 protein degradation. Compared to the clinical drug CC-90009, OX-7 and NX-7 also significantly degraded c-MYC protein. OX-7 also significantly induced c-PARP protein production, demonstrating a significant apoptosis-inducing effect, broadening its tumor indications. At a 100 nM concentration, OX-7 demonstrated a significant GSPT1 and c-MYC degradation effect starting within 2 hours of administration, with the degradation effect increasing over time, demonstrating a clear time-dependent effect. Therefore, the compounds of the present invention can be used to prepare drugs for treating or preventing diseases associated with GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutations, expression imbalances, allostery and functional abnormalities; and can be used to prepare GSPT1 degraders. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1 shows the concentration-dependent degradation of GSPT1 by the compound OX-7 of the present invention in AML cells. Figure 1A shows the degradation of GSPT1 by the compound OX-7 and the clinical drug CC-90009 in KG-1 cells; Figure 1B shows the degradation of GSPT1 by the compound OX-7 and the clinical drug CC-90009 in MOLM-13 cells.

[0059] FIG2 shows that the degradation effect of the compound OX-7 of the present invention on GSPT1 in AML cells is time-dependent.

[0060] Figure 3 shows the antiproliferative activity of the compound OX-7 of the present invention and the clinical drug CC-90009 against different tumor cells. Figures 3A and 3B show the antiproliferative activity of OX-7 and CC-90009 against KG-1 cells, respectively; and Figures 3C and 3D show the antiproliferative activity of OX-7 and CC-90009 against MOLM-13 cells, respectively. DETAILED DESCRIPTION

[0061] The technical solution of the present invention is described in detail below through specific embodiments, but the protection scope of the present invention is not limited to the embodiments.

[0062] Synthesis of key intermediate-1:

[0063] Step 1: Dissolve methyl 4-bromo-2-methylbenzoate (10.00 g, 43.86 mmol) in 200 mL of carbon tetrachloride. Add N-bromosuccinimide (15.61 g, 87.73 mmol) and azobisisobutyronitrile (0.72 g, 4.38 mmol) sequentially. After addition, heat to reflux and stir for 12 hours. The reaction is complete as monitored by TLC. Cool to room temperature, filter, and concentrate the filtrate in vacuo. The residue is purified by silica gel column chromatography (DCM:MeOH = 40:1, v / v) to afford methyl 2-4-bromo-2-(bromomethyl)benzoate (8.32 g, 62.0% yield) as a white solid.

[0064] HRMS(ESI + Calculated value: C9H9Br2O2(M+H) + ,306.8964; measured value 306.8958.

[0065] Step 2: Dissolve methyl 4-bromo-2-(bromomethyl)benzoate (8.00 g, 26.15 mmol) in 60 mL of N,N-dimethylformamide. Add 3-aminopiperidine-2,6-dione hydrochloride (5.15 g, 31.38 mmol) and DIPEA (8.45 g, 65.38 mmol) sequentially. Heat to 90°C and stir under nitrogen for 4 hours. The reaction is complete as monitored by TLC. Pour the reaction solution into 200 mL of water to precipitate a light blue solid. Allow to stand for complete precipitation, filter, and dry the filter cake in vacuo to yield a light blue solid 3: 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (5.89 g, 70.2% yield).

[0066] HRMS(ESI + ):Calculated value C 13 H 12 BrN2O3(M+H) + ,323.0026; measured value 323.0030.

[0067] Step 3: Dissolve 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (5.00 g, 15.53 mmol) in 50 mL of dry N,N-dimethylformamide, and add 1,1'-bis(diphenylphosphino)ferrocene (0.40 g, 0.71 mmol), tris(dibenzylideneacetone)dipalladium (0.39 g, 0.43 mmol) and zinc cyanide (1.88 g, 16.00 mmol) in sequence. After the addition is complete, heat to 90°C under nitrogen protection and stir for 4 hours. The reaction was complete as monitored by TLC, and the reaction was filtered and the filtrate was poured into 150 mL of water to precipitate a green solid. The reaction was allowed to stand for complete precipitation, and the filter cake was vacuum dried to obtain a light green solid 4: 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carbonitrile (3.84 g, yield 91.9%).

[0068] HRMS(ESI + ):Calculated value C 14 H 12 N3O3(M+H) + ,270.0873; measured value 270.0882.

[0069] Step 4: 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-carbonitrile (3.50 g, 13.00 mmol) was dissolved in 40 mL of N,N-dimethylformamide, and di-tert-butyl dicarbonate (5.67 g, 26.00 mmol) and 15 mL of Raney nickel were added sequentially. After addition, the mixture was heated to 50°C and stirred for 5 hours under full hydrogen replacement. The reaction was monitored by TLC. The mixture was filtered and the filter cake was washed with ethyl acetate. The filtrate was poured into 120 mL of water and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in sequence. After drying over anhydrous sodium sulfate, the mixture was concentrated in vacuo to obtain a brown solid 5: tert-butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindoline-5-yl)methyl)carbamate (3.20 g, yield 65.9%). The product was used directly in the next step without further purification.

[0070] HRMS(ESI + ):Calculated value C 19 H 24 N3O5(M+H) + ,374.1710; measured value 374.1721.

[0071] Step 5: Dissolve tert-butyl ((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)carbamate (3.00 g, 8.04 mmol) in 30 mL of a 4M hydrochloric acid-dioxane solution and stir at room temperature for 3 hours. The reaction was complete as monitored by TLC. The mixture was filtered and the filter cake was dried under vacuum to afford a pale yellow solid, Intermediate-1: 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (1.80 g, 72.4% yield). This product was used directly in the next step without further purification.

[0072] HRMS(ESI + ):Calculated value C 14 H 16 N3O3(M+H) + ,274.1186; measured value 274.1184.

[0073] Synthesis of key intermediate-2 and intermediate-3:

[0074] Step 1: Dissolve benzaldehyde (2.00 g, 18.86 mmol) in 20 mL of acetic anhydride, and add N-acetylglycine (3.31 g, 28.29 mmol) and sodium acetate (2.32 g, 28.29 mmol) sequentially. Heat to 120°C and stir for 5 hours. The reaction is complete as monitored by TLC. The reaction solution is cooled to room temperature to precipitate an orange-yellow solid. The solid is allowed to precipitate completely in an ice bath, filtered, and the filter cake is dried under vacuum to obtain a yellow solid 7: (Z)-4-benzylidene-2-methyloxazol-5(4H)-one (2.2 g, 62.5% yield). This product can be used directly in the next step without further purification.

[0075] HRMS(ESI + ):Calculated value C 11 H 10 NO2(M+H) + ,188.0706; measured value 188.0718.

[0076] Step 2: Dissolve (Z)-4-benzylidene-2-methyloxazol-5(4H)-one (2.20 g, 11.76 mmol) in 50 mL of 10% aqueous hydrochloric acid and stir at 100°C for 10 hours. TLC indicates completion of the reaction. The reaction solution is cooled to room temperature and placed in an ice bath to precipitate a brown solid. Allow to stand until precipitation is complete, filter, and vacuum dry the filter cake to yield a brown solid, Intermediate-2: 2-oxo-3-phenylpropionic acid (1.52 g, 78.7% yield). This product can be used directly in the next step without further purification.

[0077] HRMS(ESI- ): Calculated value C9H7O3(MH) - ,163.0401; measured value 163.0412.

[0078] Step 3: Dissolve 2-oxo-3-phenylpropionic acid (1.52 g, 9.27 mmol) in 20 mL of pyridine, add O-(tetrahydro-2H-pyran-2-yl)hydroxylamine (1.30 g, 11.12 mmol), and stir at room temperature under nitrogen for 12 hours. The reaction is complete as monitored by TLC. The reaction solution is poured into 1N hydrochloric acid solution and extracted with ethyl acetate. The combined organic phases are washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to afford a tan solid, Intermediate-3: (E)-3-phenyl-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propionic acid (1.95 g, 80.0% yield).

[0079] HRMS(ESI - ):Calculated value C 14 H 16 NO4(MH) - ,262.1085; measured value 262.1079.

[0080] Synthesis of key intermediate-4:

[0081] Step 1: Dissolve 2-oxo-3-phenylpropionic acid (1.52 g, 9.26 mmol) in 20 mL of pyridine, add methoxyamine hydrochloride (1.16 g, 13.89 mmol), and stir at room temperature under nitrogen for 12 hours. TLC confirms the reaction is complete. Pour the reaction solution into 1N hydrochloric acid solution and extract with ethyl acetate. The organic phases are combined, washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated in vacuo to afford a tan solid, Intermediate-4: (E)-2-(methoxyimino)-3-phenylpropionic acid (1.21 g, 67.9% yield).

[0082] HRMS(ESI - ):Calculated value C 10 H 10 NO3(MH) - ,192.0666; measured value 192.0678.

[0083] Synthesis of key intermediate-5:

[0084] Step 1: Dissolve 5-nitroisobenzofuran-1,3-dione (14.50 g, 75.00 mmol) in 20 mL of acetic acid solution, add 3-aminopiperidine-2,6-dione hydrochloride (8.20 g, 50.00 mmol) and sodium acetate (5.00 g, 60.00 mmol) in sequence, and heat to reflux and stir for 5 h. The reaction is complete as monitored by TLC. After cooling the reaction solution to room temperature, pour it into 100 mL of ice water to precipitate a white solid. Allow to stand until precipitation is complete, filter, and vacuum dry the filter cake to obtain an off-white solid 9: 2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (9.03 g, yield 62.4%). HRMS (ESI + ):Calculated value C 13 H 10 N3O6(M+H) + ,304.0564; measured value 304.0575.

[0085] Step 2: Dissolve 2-(2,6-dioxopiperidin-3-yl)-5-nitroisoindoline-1,3-dione (3.63 g, 11.98 mmol) in 10 mL of N,N-dimethylformamide, add 10% palladium on carbon (0.54 g, 5.07 mmol), and stir at room temperature for 12 hours under full hydrogen replacement. The reaction is complete as monitored by TLC, and the filtrate is filtered and poured into 100 mL of ice water to precipitate a yellow solid. Let it stand for complete precipitation, filter, and vacuum dry the filter cake to obtain a yellow solid, which is Intermediate 5: 5-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (3.00 g, yield 92.0%). HRMS (ESI + ):Calculated value C 13 H 12 N3O4(M+H) + ,274.0822; calculated value 274.0834. Synthesis of clinical drug CC-90009:

[0086] 3-(5-Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (0.10 g, 0.32 mmol) was dissolved in 5 mL of N,N-dimethylformamide. 2-(4-chlorophenyl)-2,2-difluoroacetic acid (0.08 g, 0.39 mmol) and HATU (0.19 g, 0.49 mmol) were added sequentially. After addition, the mixture was stirred at room temperature for 1 hour. DIPEA (0.13 g, 0.97 mmol) was added and stirred at room temperature overnight. The reaction was monitored for completion by TLC. The reaction solution was poured into 30 mL of ice water, resulting in the precipitation of a brown solid. The solid was allowed to stand for complete precipitation, filtered, and the filter cake was purified using silica gel column chromatography (dichloromethane:methanol = 50:1, v / v) to obtain CC-90009 as a white solid (0.10 g, 68.0% yield, 99.37% purity).

[0087] 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 9.70 (t, J = 6.1Hz, 1H), 7.68 (d, J = 7.8Hz, 1H), 7.62 (s, 4H), 7.41 (s, 1H), 7.37 (d, J = 7.8Hz, 1H),5.11(dd,J=13.3,5.0Hz,1H),4.53-4.22(m,4H),3.02-2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.30(m,1H),2.06-1.94(m,1H).

[0088] HRMS(ESI + ):Calculated value C 22 H 19 ClF2N3O4(M+H) + ,462.1027; measured value 462.1025.

[0089] Example 1 Synthesis of Compound OX-1: (E)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-phenylpropionamide:

[0090] Step 1: Dissolve (E)-3-phenyl-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid (Intermediate-3, 2.00 g, 7.60 mmol) in 10 mL of N,N-dimethylformamide. Add EDCI (2.18 g, 11.40 mmol) and HOBT (1.54 g, 11.40 mmol) sequentially. Stir at room temperature for 1 hour. Add 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (1.17 g, 3.80 mmol) and stir at room temperature overnight. The reaction was complete as monitored by TLC, and the reaction solution was poured into 30 mL of water and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in sequence, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane:methanol=50:1, v / v) to give a light yellow solid 10: (E)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindol-5-yl)methyl)-3-phenyl-2-((tetrahydro-2H-pyran-2-yl)oxy)imine)propanamide (1.01 g, yield 51.0%).

[0091] Step 2: Compound 10 (0.50 g, 0.96 mmol) was dissolved in 10 mL of 4 M hydrochloric acid-dioxane solution and stirred at room temperature for 3 hours. The reaction was complete as monitored by TLC. The mixture was filtered, and the filter cake was purified by slurrying with methanol and then vacuum dried to obtain a white solid OX-1 (0.20 g, 47.6% yield, 98.61% purity). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.96 (s, 1H), 11.02 (s, 1H), 8.70 (t, J = 6.3Hz, 1H), 7.82 (d, J = 7.7Hz, 1H), 7.45 (s, 1H), 7.35-7.20 (m, 5H), 7.13 (s, 1 H),5.11(dd,J=13.3,5.0Hz,1H),4.50-4.21(m,4H),3.85(s,2H),3.00-2 .83(m,1H),2.60(d,J=17.6Hz,1H),2.47-2.32(m,1H),2.07-1.96(m,1H).

[0092] HRMS(ESI + ):Calculated value C 23 H 23 N4O5(M+H) + ,435.1663; measured value 435.1658.

[0093] Example 2 Synthesis of Compound OX-2: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-fluorophenyl)-2-(hydroxyimino)propionamide:

[0094] Following the synthetic method of Intermediate-3, compound 11 (E)-3-(4-fluorophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid was prepared by replacing the starting material benzaldehyde with p-fluorobenzaldehyde. The total yield across the three steps was 73.7%.

[0095] HRMS(ESI - ):Calculated value C 14 H 15 FNO4(MH) - ,280.0991; measured value 280.0987.

[0096] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 11 to obtain compound 12; compound 10 was replaced by compound 12 to obtain white solid OX-2: (0.18 g, yield 42.8%, purity 99.40%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.95 (s, 1H), 11.02 (s, 1H), 8.70 (t, J = 6.3Hz, 1H), 7.66 (d, J = 7.7Hz, 1H), 7.39 (s, 1H), 7.35 (d,J=7.8Hz,1H),7.31-7.18(m,2H),7.16-7.04(m,2H),5.11(dd,J=13.3,5.0Hz,1H),4.50-4.21(m ,4H),3.82(s,2H),3.02-2.83(m,1H),2.60(d,J=18.0Hz,1H),2.47-2.31(m,1H),2.07-1.94(m,1H).

[0097] HRMS(ESI + ):Calculated value C 23 H 22 FN4O5(M+H) + ,453.1569; measured value 453.1566.

[0098] Example 3 Synthesis of Compound OX-3: (E)-3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide:

[0099] Following the synthetic method of Intermediate-3, the starting material, benzaldehyde, was replaced with p-chlorobenzaldehyde to produce Compound 13: (E)-3-(4-chlorophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield for the three steps was 49.6%. HRMS (ESI - ):Calculated value C 14 H 15 ClNO4(MH) - ,296.0695; measured value 296.0688.

[0100] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 13 to obtain compound 14: compound 10 was replaced by compound 14 to obtain white solid OX-3 (0.15 g, yield 35.7%, purity 99.02%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.99 (s, 1H), 11.02 (s, 1H), 8.71 (t, J = 6.3Hz, 1H), 7.66 (d, J = 7.7Hz, 1H), 7.39-7.31 (m, 4H), 7.23 (d, J = 8.3Hz, 2H) ,5.11(dd,J=13.3,5.0Hz,1H),4.50-4.20(m,4H),3.83(s,2H),3.01-2. 84(m,1H),2.60(d,J=17.3Hz,1H),2.48-2.29(m,1H),2.06-1.94(m,1H).

[0101] HRMS(ESI + ):Calculated value C 23 H 22 ClN4O5(M+H) + ,469.1273; measured value 469.1268.

[0102] Example 4 Synthesis of Compound OX-4: (E)-3-(4-bromophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide:

[0103] Following the synthetic method of Intermediate-3, the starting material, benzaldehyde, was replaced with p-bromobenzaldehyde to produce Compound 15: (E)-3-(4-bromophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield for the three steps was 40.3%. HRMS (ESI - ):Calculated value C 14H 15 BrNO4(MH) - ,340.0190; measured value 340.0186.

[0104] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 15 to obtain compound 16: compound 10 was replaced by compound 16 to obtain white solid OX-4 (0.17 g, yield 39.5%, purity 98.97%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 11.97 (s, 1H), 11.00 (s, 1H), 8.68 (t, J = 6.3Hz, 1H ),7.66(d,J=7.7Hz,1H),7.47(d,J=8.4Hz,2H),7.35(d,J=8.4Hz,2H),7.17(d, J=8.3Hz,2H),5.11(dd,J=13.2,5.0Hz,1H),4.50-4.18(m,4H),3.81(s,2H),3. 02-2.83(m,1H),2.60(d,J=17.6Hz,1H),2.44-2.29(m,1H),2.08-1.93(m,1H). HRMS(ESI + ):Calculated value C 23 H 22 BrN4O5(M+H) + ,513.0768; measured value 513.0767.

[0105] Example 5 Synthesis of Compound OX-5: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-nitrophenyl)propionamide:

[0106] Following the synthetic method of Intermediate-3, the starting material, benzaldehyde, was replaced with p-nitrobenzaldehyde to produce Compound 17: (E)-3-(4-nitrophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield for the three steps was 51.3%. HRMS (ESI - ):Calculated value C 14 H 15 N2O6(MH) - ,307.0936; measured value 307.0929.

[0107] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 17 to obtain compound 18: compound 10 was replaced by compound 18 to obtain white solid OX-5 (0.14 g, yield 32.5%, purity 96.83%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 12.12 (s, 1H), 10.99 (s, 1H), 8.74 (t, J = 6.3Hz, 1H), 8.16(d,J=8.7Hz,2H),7.66(d,J=7.8Hz,1H),7.48(d,J=8.6Hz,2H),7.41(s,1H),7 .37(d,J=7.8Hz,1H),5.10(dd,J=13.2,5.0Hz,1H),4.51-4.21(m,4H),3.97(s,2H) ,3.00-2.89(m,1H),2.60(d,J=16.9Hz,1H),2.46-2.28(m,1H),2.05-1.95(m,1H). HRMS(ESI + ):Calculated value C 23 H 22 N5O7(M+H) + ,480.1514; measured value 480.1510.

[0108] Example 6 Compound OX-6: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-morpholinophenyl)propionamide:

[0109] Following the synthesis of Intermediate-3, the starting material, benzaldehyde, was replaced with 4-(4-morpholino)benzaldehyde to produce Compound 19: (E)-3-(4-morpholinophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield for the three steps was 47.6%. HRMS (ESI - ):Calculated value C 18 H 23 N2O5(MH) - ,347.1612; measured value 347.1621.

[0110] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 19 to obtain compound 20; compound 10 was replaced by compound 20 to obtain white solid OX-6 (0.15 g, yield 34.8%, purity 95.80%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.79 (s, 1H), 11.00 (s, 1H), 8.62 (t, J = 6.3Hz, 1H), 7.65 (d, J =7.8Hz,1H),7.38(s,1H),7.33(d,J=7.9Hz,1H),7.09(s,1H),7.06(s,1H),6.85(s,1H),6. 82(s,1H),5.11(dd,J=13.3,5.0Hz,1H),4.49-4.20(m,4H),3.77-3.68(m,6H),3.03(t,J=4 .8Hz,4H),2.98-2.83(m,1H),2.60(d,J=17.1Hz,1H),2.45-2.28(m,1H),2.04-1.93(m,1H).

[0111] HRMS(ESI + ):Calculated value C 27 H 30 N5O6(M+H) + ,520.2191; measured value 520.2185.

[0112] Example 7 Compound OX-7: Synthesis of (E)-3-(3-chloro-4-methylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide:

[0113] Following the synthetic method of Intermediate-3, replacing the starting material benzaldehyde with 3-chloro-4-methylbenzaldehyde, Compound 21 (E)-3-(3-chloro-4-methylphenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid was prepared. The total yield across the three steps was 49.6%.

[0114] HRMS(ESI - ):Calculated value C 15 H 17 ClNO4(MH) - ,310.0852; measured value 310.0847.

[0115] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 21 to obtain compound 22; compound 10 was replaced by compound 22 to obtain white solid OX-7 (0.17 g, yield 37.2%, purity 99.05%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.96 (s, 1H), 10.99 (s, 1H), 8.69 (t, J = 6.3Hz, 1H), 7.65 (d, J=7.8Hz,1H),7.40(s,1H),7.35(d,J=7.8Hz,1H),7.24(d,J=7.8Hz,1H),7.22(s,1H),7.0 7(d,J=7.9,1.8Hz,1H),5.11(dd,J=13.3,5.1Hz,1H),4.49-4.21(m,4H),3.80(s,2H),3.0 1-2.83(m,1H),2.60(d,J=17.4Hz,1H),2.47-2.31(m,1H),2.27(s,3H),2.05-1.98(m,1H).

[0116] HRMS(ESI + ):Calculated value C 24 H 24 ClN4O5(M+H) + ,483.1430; measured value 483.1426.

[0117] Example 8 Synthesis of Compound OX-8: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-(trifluoromethoxy)phenyl)propionamide:

[0118] Following the synthetic method of Intermediate-3, compound 23 (E)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid) was prepared by replacing the starting material benzaldehyde with p-trifluoromethoxybenzaldehyde. The total yield across the three steps was 51.3%.

[0119] HRMS(ESI - ):Calculated value C 15 H 15 F3NO5(MH) - ,346.0908; measured value 346.0911.

[0120] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 23 to obtain compound 24; compound 10 was replaced by compound 24 to obtain white solid OX-8 (0.11 g, yield 25.6%, purity 98.88%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.88 (s, 1H), 11.00 (s, 1H), 8.65 (t, J = 6.3Hz, 1H) ,7.64(d,J=7.7Hz,1H),7.41(s,1H),7.34(d,J=7.8Hz,1H),7.27-7.15(m,2H),7 .08-6.90(m,2H),5.11(dd,J=13.3,5.0Hz,1H),4.50-4.21(m,4H),3.81(s,2H), 3.02-2.84(m,1H),2.60(d,J=17.5Hz,1H),2.48-2.31(m,1H),2.07-1.93(m,1H).

[0121] HRMS(ESI + ):Calculated value C 24 H 22 F3N4O6(M+H) + ,519.1486; measured value 519.1482.

[0122] Example 9 Compound OX-9: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)-3-(4-(trifluoromethyl)phenyl)propionamide:

[0123] Following the synthetic method of Intermediate-3, the starting material, benzaldehyde, was replaced with p-trifluoromethylbenzaldehyde to produce Compound 25: (E)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)-3-(4-(trifluoromethyl)phenyl)propanoic acid. The total yield for the three steps was 45.3%. HRMS (ESI - ):Calculated value C 15 H 15 F3NO4(MH) - ,330.0959; measured value 330.0961.

[0124] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 25 to obtain compound 26; compound 10 was replaced by compound 26 to obtain yellow solid OX-9 (0.12 g, yield 27.9%, purity 98.43%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.95 (s, 1H), 11.05 (s, 1H), 8.67 (t, J = 6.3Hz, 1H), 7.64 (d, J = 7.7Hz, 1H), 7.50-7.32 (m, 4H), 7.25-7.13 (m, 2H), 5.11(dd,J=13.3,5.0Hz,1H),4.51-4.22(m,4H),3.78(s,2H),2.99-2.8 3(m,1H),2.60(d,J=17.5Hz,1H),2.47-2.32(m,1H),2.08-1.94(m,1H).

[0125] HRMS(ESI + ):Calculated value C 24 H 22 F3N4O5(M+H) + ,503.1537; measured value 503.1532.

[0126] Example 10 Synthesis of Compound OX-10: (E)-3-([1,1'-biphenyl]-4-yl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(hydroxyimino)propionamide 7:

[0127] Following the synthetic method of Intermediate-3, the starting material, benzaldehyde, was replaced with p-phenylbenzaldehyde to obtain Compound 27: (E)-3-([1,1'-biphenyl]-4-yl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid. The total yield for the three steps was 43.6%. HRMS (ESI - ):Calculated value C 20 H 20 NO4(MH) - ,338.1398; measured value 338.1390.

[0128] According to the synthesis method of compound OX-1 in Example 1, the starting material intermediate-3 was replaced by compound 27 to obtain compound 28; compound 10 was replaced by compound 28 to obtain light yellow solid OX-10 (0.10 g, yield 23.3%, purity 97.28%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.90 (s, 1H), 11.05 (s, 1H), 8.70 (t, J = 6.3Hz, 1H), 7.80-7.65 (m, 4H), 7.55-7.38 (m, 4H), 7.33 (s, 1H) 7.25-7.06 (m, 3 H),5.11(dd,J=13.3,5.0Hz,1H),4.56-4.23(m,4H),3.83(s,2H),3.00-2 .83(m,1H),2.60(d,J=17.7Hz,1H),2.48-2.32(m,1H),2.07-1.95(m,1H). HRMS(ESI + ):Calculated value C 29 H 27 N4O5(M+H) + ,511.1976; measured value 511.1972.

[0129] Example 11 Synthesis of Compound OX-11: (E)-3-(3-chloro-4-methylphenyl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-(hydroxyimino)propionamide:

[0130] Step 1: Dissolve (E)-3-(3-chloro-4-methylphenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanoic acid (Compound 21, 1.25 g, 4.03 mmol) in 10 mL of N,N-dimethylformamide. Add EDCI (1.05 g, 5.49 mmol) and HOBT (0.74 g, 5.49 mmol) sequentially. Stir at room temperature for 1 hour. Add 5-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.0 g, 3.66 mmol) and stir at room temperature overnight. The reaction was complete as monitored by TLC, and the reaction solution was poured into 50 mL of water. The temperature was lowered to precipitate a yellow solid, which was filtered and dried over the filter cake. The residue was purified by silica gel column chromatography (dichloromethane:methanol=60:1, v / v) to give a yellow solid 29: (E)-3-(3-chloro-4-methylphenyl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propanamide (1.07 g, yield 50.2%).

[0131] Step 2: Compound 29 (0.20 g, 0.35 mmol) was dissolved in 10 mL of a 4 M hydrochloric acid-dioxane solution and stirred at room temperature for 20 hours. The reaction was complete as monitored by TLC. The reaction solution was concentrated in vacuo and dried. The residue was purified using silica gel column chromatography (dichloromethane:methanol = 60:1, v / v) to afford OX-11 (0.13 g, 75.0% yield, 97.77% purity) as an off-white solid. 1 H NMR (300MHz, DMSO-d6) δ (ppm) 12.40 (s, 1H), 11.13 (s, 1H), 10.64 (s, 1H), 8.34 (s, 1H), 8.20-8.11 (m, 1H), 7.89 (d, J = 8.2Hz, 1H), 7.32-7.22 (m ,2H),7.14(d,J=7.8Hz,1H),5.13(dd,J=12.9,5.3Hz,1H),3.90(s,2H) ,2.98-2.80(m,1H),2.66-2.53(m,2H),2.27(s,3H),2.11-2.00(m,1H). HRMS(ESI + ):Calculated value C 23 H 20 ClN4O6(M+H) + ,483.1066; measured value 483.1060.

[0132] Example 12 Synthesis of Compound OX-12: (E)-N-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-3-(4-fluorophenyl)-2-(hydroxyimino)propionamide:

[0133] According to the synthesis method of compound OX-11 in Example 11, the starting material compound 21 was replaced by compound 11: (E)-3-(4-fluorophenyl)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)propionic acid to obtain compound 30; compound 29 was replaced by compound 30 to obtain light yellow solid OX-12 (0.10 g, yield 58.8%, purity 96.95%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 12.05 (s, 1H), 11.03 (s, 1H), 10.58 (s, 1H), 8.30 (s, 1H), 8.20-8.09 (m, 1H), 7.95 (d, J = 8.2Hz, 1H), 7.40-7.28 (m, 1H) ),7.24-7.08(m,3H),5.13(dd,J=12.9,5.3Hz,1H),3.88(s,2H),2.98-2. 82(m,1H),2.59(d,J=17.5Hz,1H),2.48-2.32(m,1H),2.09-1.94(m,1H). HRMS(ESI + ):Calculated value C 22 H 18 FN4O6(M+H) + ,453.1205; measured value 453.1200.

[0134] Example 13 Synthesis of Compound OX-13: (E)-N-(2-(2,6-dioxapiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)-2-(hydroxyimino)-3-(4-(trifluoromethyl)phenyl)propionamide:

[0135] According to the synthesis method of compound OX-11 in Example 11, the starting material compound 21 was replaced by compound 25: (E)-2-(((tetrahydro-2H-pyran-2-yl)oxy)imino)-3-(4-(trifluoromethyl)phenyl)propanoic acid to obtain compound 31; compound 29 was replaced by compound 31 to obtain a light yellow solid OX-13 (0.09 g, yield 52.9%, purity 97.29%). 1 H NMR (300MHz, DMSO-d6) δ (ppm) 12.01 (s, 1H), 10.98 (s, 1H), 10.44 (s, 1H), 8.33 (s, 1H), 8.15-8.04 (m, 1H), 7.95 (d, J = 8.2Hz, 1H), 7.48-7.32 (m, 1H) ),7.23-7.08(m,3H),5.11(dd,J=12.9,5.3Hz,1H),3.90(s,2H),3.00-2. 82(m,1H),2.60(d,J=17.7Hz,1H),2.48-2.32(m,1H),2.10-1.96(m,1H). HRMS(ESI + ):Calculated value C 23 H 18 F3N4O6(M+H) +,503.1173; measured value 503.1168.

[0136] Example 14 Synthesis of Compound NX-1: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-hydrazinylidene-3-phenylpropionamide:

[0137] Step 1: Dissolve 2-oxo-3-phenylpropionic acid (Intermediate-2, 1.06 g, 6.47 mmol) in 10 mL of N,N-dimethylformamide. Add EDCI (1.24 g, 6.47 mmol) and HOBT (0.87 g, 6.47 mmol) sequentially. Stir at room temperature for 1 hour. Add 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (1.00 g, 3.23 mmol) and stir at room temperature overnight. The reaction was complete as monitored by TLC, and the reaction solution was poured into 50 mL of water and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in that order, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane:methanol=65:1, v / v) to give a brown solid 32: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-phenylpropanamide (0.83 g, yield 59.0%).

[0138] Step 2: Compound 32 (0.50 g, 1.15 mmol) was dissolved in 10 mL of acetic acid solution (50%), and 80% hydrazine hydrate (0.07 g, 1.15 mmol) was added. The mixture was stirred at room temperature for 5 h. The reaction was completed as monitored by TLC. The reaction solution was poured into 50 mL of saturated sodium bicarbonate solution and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in sequence. After drying over anhydrous sodium sulfate, the mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane: methanol = 70: 1, v / v) to give NX-1 (0.15 g, yield 30.0%, purity 98.37%) as a light yellow solid. 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.49 (t, J = 6.4Hz, 1H), 7.82 (d, J =7.8Hz,1H),7.51(s,1H),7.38(d,J=9.1Hz,1H),7.30(s,3H),7.21(s,2H),6. 62(s,2H),5.13(dd,J=13.3,5.1Hz,1H),4.50-4.25(m,4H),3.81(s,2H),2.9 9-2.85(m,1H),2.60(d,J=17.0Hz,1H),2.47-2.33(m,1H),2.08-1.94(m,1H). HRMS(ESI + ):Calculated value C 23 H 24 N5O4(M+H) + ,434.1823; measured value 434.1816.

[0139] Example 15 Synthesis of Compound NX-2: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-3-(4-fluorophenyl)-2-oxopropionamide:

[0140] According to the synthetic method of intermediate-2, the starting material benzaldehyde was replaced with p-fluorobenzaldehyde to obtain compound 33: 3-(4-fluorophenyl)-2-oxopropionic acid. The total yield of the two steps was 68.5%. HRMS (ESI - ): Calculated value C9H6FO3(MH) - ,181.0306; measured value 181.0306.

[0141] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 33 to obtain compound 34; compound 32 was replaced by compound 34 to obtain yellow solid NX-2 (0.13 g, yield 26.0%, purity 99.60%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.99 (s, 1H), 8.39 (t, J = 6.4Hz, 1H), 7.75 (d, J = 7.8Hz, 1H), 7.50 (s, 1H), 7.38-7.22 (m, 3H), 7.15-7.04 (m, 2H), 6.49 (s ,2H),5.13(dd,J=13.3,5.1Hz,1H),4.50-4.23(m,4H),3.75(s,2H),3.00- 2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.08-1.94(m,1H). HRMS(ESI + ):Calculated value C 23 H 23 FN5O4(M+H) + ,452.1729; measured value 452.1726.

[0142] Example 16 Synthesis of Compound NX-3: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-(p-tolyl)propionamide:

[0143] According to the synthesis method of Intermediate-2, the starting material benzaldehyde was replaced with p-methylbenzaldehyde to obtain compound 35: 2-oxo-3-(p-tolyl)propionic acid. The total yield of the two steps was 65.3%. HRMS (ESI - ):Calculated value C 10 H9O3(MH) - ,177.0557; measured value 177.0568.

[0144] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 35 to obtain compound 36; compound 32 was replaced by compound 36 to obtain brown solid NX-3 (0.17 g, yield 34.0%, purity 97.49%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 8.45 (t, J=6.4Hz, 1H), 7.75 (d, J= 7.8Hz,1H),7.50(s,1H),7.34-7.20(m,3H),7.12-7.02(m,2H),6.45(s,2H),5 .11(dd,J=13.3,5.1Hz,1H),4.50-4.23(m,4H),3.75(s,2H),3.00-2.85(m,1H ), 2.60 (d, J = 17.5Hz, 1H), 2.47-2.32 (m, 1H), 2.20 (s, 3H), 2.07-1.92 (m, 1H). HRMS(ESI + ):Calculated value C 24 H 26 N5O4(M+H) + ,448.1980; measured value 448.1976.

[0145] Example 17 Synthesis of Compound NX-4: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-(4-(trifluoromethoxy)phenyl)propionamide:

[0146] According to the synthesis method of Intermediate-2, the starting material benzaldehyde was replaced with p-trifluoromethoxybenzaldehyde to obtain compound 37: 2-oxo-3-(4-(trifluoromethoxy)phenyl)propanoic acid. The total yield of the two steps was 62.3%. HRMS (ESI - ):Calculated value C 10 H9O3(MH) - ,177.0557; measured value 177.0568.

[0147] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 37 to obtain compound 38; compound 32 was replaced by compound 38 to obtain yellow-white solid NX-4 (0.11 g, yield 22.0%, purity 99.33%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.10 (s, 1H), 8.56 (t, J = 6.4Hz, 1H), 7.83 (d, J = 7.8Hz, 1H), 7.45 (s, 1H), 7.35-7.19 (m, 3H), 6.99-6.87 (m, 2H), 6.28 (s ,2H),5.11(dd,J=13.3,5.1Hz,1H),4.46-4.20(m,4H),3.84(s,2H),3.00- 2.83(m,1H),2.59(d,J=17.0Hz,1H),2.47-2.30(m,1H),2.09-1.94(m,1H). HRMS(ESI + ):Calculated value C 24 H 23 F3N5O5(M+H) + ,518.1646; measured value 518.1642.

[0148] Example 18 Synthesis of Compound NX-5: 3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxopropanamide:

[0149] According to the synthesis method of Intermediate-2, the starting material benzaldehyde was replaced with p-chlorobenzaldehyde to obtain compound 39: 3-(4-chlorophenyl)-2-oxopropionic acid. The total yield of the two steps was 52.4%. HRMS (ESI - ): Calculated value C9H6ClO3 (MH) - ,197.0011; measured value 197.0021.

[0150] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 39 to obtain compound 40; compound 32 was replaced by compound 40 to obtain yellow-white solid NX-5 (0.14 g, yield 28.0%, purity 97.90%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.95 (s, 1H), 8.40 (t, J = 6.4Hz, 1H), 7.88 (d, J=7.8Hz,1H),7.48(s,1H),7.40-7.29(m,3H),7.22(d,J=7.8Hz,2H),6.33( s,2H),5.11(dd,J=13.3,5.1Hz,1H),4.49-4.23(m,4H),3.80(s,2H),3.02- 2.84(m,1H),2.60(d,J=17.7Hz,1H),2.47-2.33(m,1H),2.07-1.93(m,1H). HRMS(ESI + ):Calculated value C 23 H 23 ClN5O4(M+H) + ,468.1433; measured value 468.1427.

[0151] Example 19 Synthesis of Compound NX-6: N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxo-3-(4-(trifluoromethyl)phenyl)propionamide:

[0152] According to the synthetic method of Intermediate-2, the starting material benzaldehyde was replaced with p-trifluoromethylbenzaldehyde to obtain compound 41: 2-oxo-3-(4-(trifluoromethyl)phenyl)propanoic acid. The total yield of the two steps was 53.6%. HRMS (ESI - ):Calculated value C 10 H6F3O3(MH) - ,231.0275; measured value 231.0268.

[0153] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 41 to obtain compound 42; compound 32 was replaced by compound 42 to obtain light yellow solid NX-6 (0.10 g, yield 20.0%, purity 97.51%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.01 (s, 1H), 8.49 (t, J = 6.3 Hz, 1H), 7.83 (d, J =7.8Hz,1H),7.55-7.43(m,3H),7.37-7.29(m,2H),7.19(d,J=7.0Hz,1H),6. 28(s,2H),5.11(dd,J=13.3,5.1Hz,1H),4.51-4.25(m,4H),3.85(s,2H),2.9 8-2.85(m,1H),2.58(d,J=17.0Hz,1H),2.47-2.32(m,1H),2.10-1.94(m,1H). HRMS(ESI + ):Calculated value C 24 H 23 F3N5O4(M+H) + ,502.1697; measured value 502.1694.

[0154] Example 20 Synthesis of Compound NX-7: 3-(3-chloro-4-methylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)methyl)-2-oxopropanamide:

[0155] According to the synthesis method of Intermediate-2, the starting material benzaldehyde was replaced with 3-chloro-4-methylbenzaldehyde to obtain compound 43: 3-(3-chloro-4-methylphenyl)-2-oxopropionic acid. The total yield of the two steps was 58.2%. HRMS (ESI - ):Calculated value C 10 H8ClO3(MH) - ,211.0167; measured value 211.0159.

[0156] According to the synthesis method of compound NX-1 in Example 14, the starting material intermediate-2 was replaced by compound 43 to obtain compound 44; compound 32 was replaced by compound 44 to obtain light yellow-white solid NX-7 (0.15 g, yield 30.0%, purity 97.31%). 1H NMR (400MHz, DMSO-d6) δ (ppm) 11.02 (s, 1H), 8.37 (t, J = 6.4Hz, 1H), 7.66 (d, J = 7.8Hz ,1H),7.43(s,1H),7.40-7.32(m,3H),7.25(s,1H),7.23(d,J=7.8Hz,1H),7.09(d,J= 9.5Hz,1H),5.11(dd,J=13.3,5.1Hz,1H),4.51-4.21(m,4H),3.75(s,2H),2.96-2.8 5(m,1H),2.60(d,J=17.3Hz,1H),2.45-2.31(m,1H),2.26(s,3H),2.03-1.94(m,1H). HRMS(ESI + ):Calculated value C 24 H 25 ClN5O4(M+H) + ,482.1590; measured value 482.1578.

[0157] Example 21 Synthesis of Compound CX-1: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-phenylpropionamide:

[0158] (E)-2-(Methoxyimino)-3-phenylpropionic acid (Intermediate-4, 0.31 g, 1.62 mmol) was dissolved in 6 mL of N,N-dimethylformamide, and EDCI (0.38 g, 2.02 mmol) and HOBT (0.27 g, 2.02 mmol) were added in sequence. After the addition, the mixture was stirred at room temperature for 1 hour. 3-(5-aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (Intermediate-1, 0.25 g, 0.81 mmol) was added and stirred at room temperature overnight. The reaction was complete as monitored by TLC, and the reaction solution was poured into 30 mL of water and extracted with ethyl acetate. The organic phases were combined and washed with water and saturated brine in sequence, dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane: methanol = 60: 1, v / v) to give an off-white solid CX-1 (0.08 g, 22.2%, purity 97.85%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 9.08 (t, J = 6.1Hz, 1H), 7.86 (d, J = 7.8Hz, 1H), 7.52 (s, 1H), 7.35-7.10 (m, 6H), 5.11 (dd, J = 13.3 ,5.0Hz,1H),4.50-4.23(m,4H),3.98(s,3H),3.85(s,2H),3.00-2.83(m,1H),2.60(d,J=17.3Hz,1H),2.46-2.34(m,1H),2.08-1.95(m,1H). HRMS(ESI + ):Calculated value C 24 H 25 N4O5(M+H) + ,449.1820; measured value 449.1816.

[0159] Example 22 Synthesis of Compound CX-2: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-(p-tolyl)propionamide:

[0160] Following the synthetic methods of Intermediate-2 and Intermediate-4, the starting material benzaldehyde was replaced with p-methylbenzaldehyde to obtain compound 45: (E)-2-(methoxyimino)-3-(p-tolyl)propanoic acid. The total yield of the three steps was 62.5%. HRMS (ESI - ):Calculated value C 11 H 12 NO3(MH) - ,206.0823; measured value 206.0835.

[0161] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 45 to obtain an off-white solid CX-2 (0.11 g, yield 29.7%, purity 98.34%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.99 (t, J = 6.1Hz, 1H), 7.95 (d, J = 7.8Hz, 1H),7.52(s,1H),7.35(d,J=7.7Hz,2H),7.20(d,J=7.8Hz,1H),7.05(d,J=7.5Hz,2H) ,5.11(dd,J=13.3,5.0Hz,1H),4.52-4.25(m,4H),3.95(s,3H),3.82(s,2H),2.99-2. 81(m,1H),2.60(d,J=17.7Hz,1H),2.47-2.31(m,1H),2.23(s,3H),2.08-1.92(m,1H). HRMS(ESI + ):Calculated value C 25 H 27 N4O5(M+H) + ,463.1976; measured value 463.1972.

[0162] Example 23 Synthesis of Compound CX-3: (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(4-fluorophenyl)-2-(methoxyimino)propionamide:

[0163] Following the synthetic methods of Intermediate-2 and Intermediate-4, the starting material benzaldehyde was replaced with p-fluorobenzaldehyde to obtain compound 46: (E)-3-(4-fluorophenyl)-2-(methoxyimino)propionic acid. The total yield of the three steps was 65.3%. HRMS (ESI - ):Calculated value C 10 H9FNO3(MH) - , 210.0572; measured value 210.0568.

[0164] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 46 to obtain white solid CX-3 (0.13 g, yield 34.4%, purity 99.19%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.99 (s, 1H), 8.89 (t, J = 6.1Hz, 1H), 7.92 (d, J=7.6Hz,1H),7.55(s,1H),7.35-7.25(m,3H),7.05(t,J=8.9Hz,2H),5.11( dd,J=13.3,5.0Hz,1H),4.50-4.25(m,4H),3.97(s,3H),3.78(s,2H),3.00- 2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.08-1.95(m,1H). HRMS(ESI + ):Calculated value C 24 H 24 FN4O5(M+H) + ,467.1725; measured value 467.1720.

[0165] Example 24 Compound CX-4: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-3-(3-fluorophenyl)-2-(methoxyimino)propionamide:

[0166] Following the synthetic methods of Intermediate-2 and Intermediate-4, the starting material benzaldehyde was replaced with 3-fluorobenzaldehyde to obtain compound 47: (E)-3-(3-fluorophenyl)-2-(methoxyimino)propionic acid. The total yield of the three steps was 55.7%. HRMS (ESI - ):Calculated value C 10 H9FNO3(MH) - ,210.0572; measured value 210.0563.

[0167] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 47 to obtain an off-white solid CX-4 (0.10 g, yield 26.5%, purity 98.62%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 8.86 (t, J = 6.1 Hz, 1H), 7.88 (d, J = 7. 6Hz,1H),7.48(s,1H),7.35-7.26(m,2H),7.15(d,J=7.5Hz,2H),7.05-6.94(m,1 H),5.11(dd,J=13.3,5.0Hz,1H),4.45-4.21(m,4H),3.95(s,3H),3.82(s,2H),3 .02-2.85(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.10-1.95(m,1H). HRMS(ESI + ):Calculated value C 24 H 24 FN4O5(M+H) + ,467.1725; measured value 467.1718.

[0168] Example 25 Synthesis of Compound CX-5: (E)-3-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)propionamide:

[0169] Following the synthetic methods of Intermediate-2 and Intermediate-4, the starting material benzaldehyde was replaced with p-chlorobenzaldehyde to obtain compound 48: (E)-3-(4-chlorophenyl)-2-(methoxyimino)propionic acid. The total yield of the three steps was 59.6%. HRMS (ESI - ):Calculated value C 10 H9ClNO3(MH) - ,226.0276; measured value 226.0268.

[0170] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 48 to obtain a white solid CX-5 (0.10 g, yield 25.6%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 10.90 (s, 1H), 9.05 (t, J = 6.1Hz, 1H), 7.76 (d, J=7.6Hz,1H),7.50(s,1H),7.36-7.28(m,3H),7.16(t,J=8.9Hz,2H),5.11( dd,J=13.3,5.0Hz,1H),4.52-4.28(m,4H),3.95(s,3H),3.79(s,2H),2.97- 2.82(m,1H),2.60(d,J=17.0Hz,1H),2.47-2.32(m,1H),2.08-1.96(m,1H). HRMS(ESI + ):Calculated value C 24 H 24 ClN4O5(M+H) + ,483.1430; measured value 483.1428.

[0171] Example 26 Compound CX-6: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-(4-(trifluoromethyl)phenyl)propionamide:

[0172] Following the synthetic methods of Intermediate-2 and Intermediate-4, the starting material, benzaldehyde, was replaced with p-trifluoromethylbenzaldehyde to obtain compound 49: (E)-2-(methoxyimino)-3-(4-(trifluoromethyl)phenyl)propanoic acid. The total yield for the three steps was 61.3%. HRMS (ESI - ):Calculated value C 11 H9F3NO3(MH) - ,260.0540; measured value 260.0537.

[0173] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 49 to obtain a gray solid CX-6 (0.09 g, yield 21.4%, purity 98.42%). 1H NMR(300MHz,DMSO-d6)δ(pp m)11.00(s,1H),8.94(t,J=6.1Hz,1H),7.80(d,J=7.6Hz,1H),7.52-7.44(m,3H),7.33-7.21(m,3H),5.11(dd,J=13.3,5.0Hz,1H ),4.50-4.25(m,4H),3.99(s,3H),3.75(s,2H),2.98-2.83(m,1H),2.61(d,J=17.3Hz,1H),2.48-2.33(m,1H),2.10-1.96(m,1H). HRMS(ESI + ):Calculated value C 25 H 24 F3N4O5(M+H) + ,517.1694; measured value 517.1691.

[0174] Example 27 Compound CX-7: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)-3-(4-(trifluoromethoxy)phenyl)propionamide:

[0175] Following the synthetic methods of Intermediates-2 and -4, the starting material, benzaldehyde, was replaced with p-trifluoromethoxybenzaldehyde to obtain Compound 50: (E)-2-(methoxyimino)-3-(4-(trifluoromethoxy)phenyl)propanoic acid. The total yield for the three steps was 62.5%. HRMS (ESI - ):Calculated value C 11 H9F3NO4(MH) - ,276.0489; measured value 276.0475.

[0176] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 50 to obtain an off-white solid CX-7 (0.08 g, yield 18.6%, purity 98.66%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.94 (t, J = 6.1Hz, 1H), 7.80 (d, J = 7.6 Hz,1H),7.49(s,1H),7.34(d,J=7.2Hz,1H),7.21(d,J=7.0Hz,2H),6.90(d,J=7.5H z,2H),5.11(dd,J=13.3,5.0Hz,1H),4.46-4.24(m,4H),3.98(s,3H),3.78(s,2H) ,3.01-2.83(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.32(m,1H),2.07-1.96(m,1H). HRMS(ESI + ):Calculated value C 25 H 24 F3N4O6(M+H) + ,533.1643; measured value 533.1636.

[0177] Example 28 Synthesis of Compound CX-8: (E)-3-(3-chloro-4-methylphenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)propionamide:

[0178] Following the synthetic methods of Intermediate-2 and Intermediate-4, the starting material, benzaldehyde, was replaced with 3-chloro-4-methylbenzaldehyde to obtain Compound 51: (E)-3-(3-chloro-4-methylphenyl)-2-(methoxyimino)propionic acid. The total yield for the three steps was 65.6%. HRMS (ESI - ):Calculated value C 11 H 11 ClNO3(MH) - ,240.0433; measured value 240.0438.

[0179] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 51 to obtain white solid CX-8 (0.13 g, yield 32.5%, purity 99.92%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.00 (s, 1H), 8.86 (d, J = 6.6Hz, 1H), 7.65 (d, J = 7.8Hz, 1H) ,7.40(s,1H),7.35(d,J=7.7Hz,1H),7.25(d,J=7.8Hz,1H),7.19(s,1H),7.05(d,J=7.9H z,1H),5.11(dd,J=13.3,5.0Hz,1H),4.52-4.21(m,4H),3.98(s,3H),3.80(s,2H),3.00- 2.81(m,1H),2.61(d,J=15.3Hz,1H),2.45-2.34(m,1H),2.27(s,3H),2.08-1.92(m,1H). HRMS(ESI + ):Calculated value C 25 H 26 ClN4O5(M+H) + ,497.1586; measured value 497.1582.

[0180] Example 29 Compound CX-9: Synthesis of (E)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(4-fluorophenyl)-2-(methoxyimino)acetamide:

[0181] According to the synthesis method of Intermediate-4, the starting material Intermediate-2 was replaced with 2-(4-fluorophenyl)-2-oxoacetic acid to obtain Compound 52: (Z)-2-(4-fluorophenyl)-2-(methoxyimino)acetic acid with a yield of 78.3%. HRMS (ESI - ): Calculated value C9H7FNO3(MH) - ,196.0415; measured value 196.0425.

[0182] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced by compound 52 to obtain a yellow-white solid CX-9 (0.09 g, yield 25.0%, purity 96.88%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.01 (s, 1H), 9.34 (t, J = 6.1Hz, 1H), 7.73 (d, J = 7.9Hz, 1H), 7.65-7.54 (m, 3H), 7.50 (d, J = 7.9Hz, 1H), 7.30 (t, J = 8.9Hz ,2H),5.13(dd,J=13.2,5.1Hz,1H),4.63-4.26(m,4H),3.96(s,3H),3.00- 2.85(m,1H),2.61(d,J=17.4Hz,1H),2.45-2.33(m,1H),2.07-1.97(m,1H). HRMS(ESI + ):Calculated value C 23 H 22 FN4O5(M+H) + ,453.1569; measured value 453.1568.

[0183] Example 30 Compound CX-10: Synthesis of (E)-2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)acetamide:

[0184] According to the synthesis method of Intermediate-4, the starting material Intermediate-2 was replaced with 2-(4-fluorophenyl)-2-oxoacetic acid to obtain Compound 53: (Z)-2-(4-chlorophenyl)-2-(methoxyimino)acetic acid with a yield of 75.6%. HRMS (ESI - ): Calculated value C9H7ClNO3(MH) - ,212.0120; measured value 212.0131.

[0185] According to the synthesis method of compound CX-1 in Example 21, the starting material intermediate-4 was replaced with compound 53 to obtain a light yellow solid CX-10 (0.10 g, yield 26.3%, purity 98.12%). 1H NMR (300MHz, DMSO-d6) δ (ppm) 11.05 (s, 1H), 9.25 (t, J= 6.1Hz,1H),7.79(d,J=7.9Hz,1H),7.66-7.54(m,3H),7.48(d,J=7.9Hz,1H),7.25(t,J=8.9Hz,2H),5.11(dd,J=13.2,5.1 Hz,1H),4.55-4.26(m,4H),3.90(s,3H),2.98-2.82(m,1H),2.60(d,J=17.3Hz,1H),2.47-2.33(m,1H),2.08-1.99(m,1H). HRMS(ESI + ):Calculated value C 23 H 22 ClN4O5(M+H) + ,469.1273; measured value 469.1269.

[0186] Example 31 Compound CX-11: Synthesis of (E)-2-(2-aminothiazol-4-yl)-N-((2-(2,6-dioxopyrimidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2-(methoxyimino)acetamide hydrochloride:

[0187] Step 1: (E)-2-(2-Aminothiazol-4-yl)-2-(methoxyimino)acetic acid (compound 54, 0.5 g, 2.48 mmol) was dissolved in a mixed solvent of 4 mL of N,N-dimethylformamide and 10 mL of tetrahydrofuran. 4 mL of a tetrahydrofuran solution of sodium bis(trimethylsilyl)amide (2 M) was added dropwise under ice bath. After the addition was complete, the mixture was stirred under ice bath for 1 h. Di-tert-butyl dicarbonate (0.58 g, 2.68 mmol) was added dropwise at 0°C. After the addition was complete, the mixture was stirred at room temperature for 2 h. The reaction was complete as monitored by TLC, and the reaction solution was concentrated in vacuo. The residue was poured into 20 mL of water and the pH was adjusted to 3-4 with dilute hydrochloric acid (3 M) to precipitate a yellow-white solid. The solid was allowed to stand for complete precipitation, and then filtered and the filter cake was dried to give a light yellow solid 55: (E)-2-(2-((tert-butoxycarbonyl)amino)thiazol-4-yl)-2-(methoxyimino)acetic acid (0.26 g, yield 34.6%).

[0188] Step 2: 3-(5-Aminomethyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride (Intermediate-1, 0.15 g, 0.49 mmol) was dissolved in 6 mL of N,N-dimethylformamide. Compound 55 (0.15 g, 0.49 mmol) and HATU (0.28 g, 0.74 mmol) were added sequentially. After addition, the mixture was stirred at room temperature for 1 hour. DIPEA (0.19 g, 1.47 mmol) was added and the mixture was stirred at room temperature overnight. The reaction was complete as monitored by TLC, and the reaction solution was poured into 30 mL of ice water to precipitate a brown solid. The solution was allowed to stand for complete precipitation and filtered. The filter cake was purified using a silica gel column chromatography (dichloromethane:methanol = 50:1, v / v) to give a brown-yellow solid 56: (E)-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)amino)-1-(methoxyimino)-2-oxoethyl)thiazol-2-yl)carbamic acid tert-butyl ester (0.11 g, yield 40.7%).

[0189] Step 3: Dissolve compound 56 (0.11 g, 0.19 mmol) in 30 mL of 4 M hydrochloric acid-dioxane solution and stir at room temperature for 3 hours. The reaction was complete as monitored by TLC. The mixture was filtered and the filter cake was dried under vacuum to obtain a light yellow solid CX-11 (0.04 g, 45.9% yield, 98.87% purity). 1 HNMR(300MHz,DMSO-d6)δ(ppm)11.01(s,1H),9.08(t,J=6.1Hz,1H),7.95(s,1H),7.74(d,J=7.8Hz,1H),7.56(s,1H),7.49(d,J=7.9Hz,1H),7.26(s, 2H),5.13(dd,J=13.3,5.0Hz,1H),4.53-4.28(m,4H),3.99(s,3H),3.01-2 .85(m,1H),2.60(d,J=19.1Hz,1H),2.45-2.30(m,1H),2.07-1.96(m,1H). HRMS(ESI + ):Calculated value C 20 H 21 N6O5S(M+H) + ,457.1289; measured value 457.1278.

[0190] Biological Test Example 1: Study on the degradation of GSPT1 in KG-1 cells.

[0191] KG-1 cells (ATCC) were grown in IMDM (containing 20% ​​FBS) and the cell concentration was adjusted to 10 6Cells / well were plated in 6-well plates with 1350 μl per well. 150 μl of DMSO and the test compound of the present invention were added at a concentration of 200 nM and cultured in a 5% CO2, 37°C incubator for 4 hours. The cells were centrifuged to discard the culture medium, and PBS was added for washing and discarded. Whole-cell lysates were prepared using a mixture containing protease inhibitors (100×, Ford Biotech), a protein phosphatase inhibitor mixture (100×, Ford Biotech), a super nuclease (Biyuntian) and a high-intensity RIPA lysis buffer (Thermo Fisher Scientific) and placed on ice for 30 minutes. The cell debris pellet was discarded by centrifugation, and the supernatant whole-cell lysate was collected and transferred to a new centrifuge tube. After performing the BCA protein assay, the sample was prepared using 5X loading buffer (Thermo Fisher Scientific). Proteins were separated by electrophoresis on a 4-20% precast SDS-PAGE gel and transferred to a PVDF membrane. The membrane was blocked with 5% NFDM / TBST at room temperature for 1 hour. The membrane was then incubated with the primary antibody overnight at 4°C and the secondary antibody for 2 hours at room temperature the following day. Signals were detected using a MINICHEM™ imaging system.

[0192] The control group was the blank solvent group.

[0193] The following antibodies were used in this test case:

[0194] Primary Antibody:

[0195] Anti-GSPT1: Abcam ab234433

[0196] Anti-IKZF1:Cell signaling technology(CST)5443S

[0197] Anti-IKZF3:Cell signaling technology(CST)15103S

[0198] Anti-beta Actin: Fude Bio FD0060

[0199] Secondary Antibody:

[0200] Anti-rabbit peroxidase-linked secondary antibody: FDG007

[0201] The degradation effects of the compounds on GSPT1 protein are shown in Table 1, wherein A indicates that the degradation percentage of GSPT1 protein is not less than 80%, B indicates that the degradation percentage is less than 80% but not less than 50%, C indicates that the degradation percentage is less than 50% but not less than 25%, and D indicates that the degradation percentage is less than 25%.

[0202] Table 1 Degradation of GSPT1 protein by compounds

[0203] As can be seen from the table, compared to the clinical drug CC-90009, the degradation efficiency of the dominant compounds in each series of the present invention is superior to that of the clinical drug, while the degradation efficiency of most other compounds is comparable to that of the clinical drug. This indicates that the OX, NX, and CX series of oxime compounds significantly enhance the degradation of GSPT1 protein.

[0204] The present invention uses compound OX-7 as an example to provide graphs demonstrating its concentration-dependent and time-dependent degradation of GSPT1 in AML cells, as shown in Figures 1 and 2. Figure 1A shows the degradation of GSPT1 by compound OX-7 and the clinical drug CC-90009 in KG-1 cells. Figure 1B shows the degradation of GSPT1 by compound OX-7 and the clinical drug CC-90009 in MOLM-13 cells.

[0205] As can be seen from the figure, the degradation effect of the compound OX-7 of the present invention on GSPT1 in KG-1 and MOLM-13 cells is concentration-dependent and time-dependent, and the effect is more significant than that of CC-90009.

[0206] Biological test example 2: Anti-KG-1 cell proliferation activity of the compounds of the present invention.

[0207] KG-1 cells in the logarithmic growth phase were diluted with culture medium (RPMI + 10% FBS) and plated in 96-well plates at 5000 cells / well. The cells were cultured in a 5% CO2, 37°C incubator for 24 hours. The test compound of the present invention was prepared into a 10mM stock solution with DMSO and diluted with culture medium to set up 9 concentration gradients, with 3 replicates for each concentration. After drug addition, the cells were cultured in a 5% CO2, 37°C incubator for 72 hours. Cell proliferation was detected using the CCK8 method. The IC value of the compound on cell growth inhibition was determined using the enzyme-labeled assay. 50 IC values ​​were calculated using GraphPad Prism 7 software. 50 value.

[0208] The anti-proliferation activity of the compounds against KG-1 cells is shown in Table 2, where A represents IC 50 <1nM, B means 1≤IC 50 <10nM, C means 10nM≤IC 50 <100nM, D means 100nM≤IC 50 <1000nM, E represents IC 50 ≥1000nM.

[0209] Table 2 Anti-proliferation activity of compounds in KG-1 cells

[0210] From the anti-proliferative activity of each series of compounds in the table, it can be seen that the anti-proliferative inhibitory activity of the OX, NX, and CX series of compounds of the present invention on KG-1 cells is significantly improved, which is better than the clinical drug CC-90009. Among them, the superior compounds of each series such as OX-7, NX-7, CX-7, and CX-8 have excellent anti-proliferative inhibitory activity, IC 50 At 1-10nM.

[0211] Biological Test Example 3: The compounds of the present invention have anti-proliferative activity against various tumor cells.

[0212] U937, MOLM-13, and MV4-11 cells (ATCC) in the logarithmic growth phase were diluted with culture medium and plated in 96-well plates at 5000 cells / well. The cells were cultured in a 5% CO2, 37°C incubator for 24 hours. The compound was prepared into a 10mM stock solution with DMSO and diluted with culture medium to set up 9 concentration gradients, with 3 replicates for each concentration. After drug addition, the cells were cultured in a 5% CO2, 37°C incubator for 72 hours. Cell proliferation was detected using the CCK8 method. The IC value of the compound on cell growth inhibition was determined using enzyme-labeled immunosorbent assay. 50 IC values ​​were calculated using GraphPad Prism 7 software. 50 value.

[0213] The anti-tumor cell proliferation activities of the compounds are shown in Table 3, where A represents IC 50 <1nM, B means 1≤IC 50 <10nM, C means 10nM≤IC 50 <100nM, D means 100nM≤IC 50 <1000nM, E represents IC 50 ≥1000nM.

[0214] Table 3 Anti-tumor cell proliferation activity of compounds

[0215] As can be seen from the table, compared to the clinical drug CC-90009, the dominant compounds in each series of compounds of the present invention exhibited superior antiproliferative activity, while the other compounds were comparable to CC-90009. Therefore, it can be seen that the OX, NX, and CX series of oxime compounds of the present invention exhibit significantly enhanced antiproliferative activity against various AML cell lines.

[0216] As described above, although the present invention has been shown and described with reference to specific preferred embodiments, it should not be construed as limiting the present invention itself. Various changes may be made to it in form and detail without departing from the spirit and scope of the present invention as defined in the appended claims.

Claims

1. A compound represented by the general formula I or a pharmaceutically acceptable salt, tautomer, mesomer, racemate, enantiomer, diastereomer thereof: in: X is selected from -OH, -NH 2 、-OCH 3 or -NHCOCH 3 ; Ring Y is selected from C 6 -C 12 Aryl, 5-10 membered heteroaryl, C 3 -C 8 Cycloalkyl or 3-10 membered heterocyclyl, the aryl, heteroaryl, cycloalkyl and heterocyclyl are unsubstituted or optionally substituted with 1-3 R a replace; R 1 Selected from R 2 Selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace; Each R 3 are independently selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace; R 4 Selected from hydrogen, deuterium, halogen or C 1 -C 6 alkyl; R 5 Selected from hydrogen, deuterium, C 1 -C 12 alkyl, Z is selected from -CH 2 -, -CD 2 -, -C(O)- or -C(S)-; R 6 , R 7 , R 8 , R 9 , R 10 , R 11 are independently selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl group is unsubstituted or optionally substituted with 1-3 R a replace; Each R a , R b are independently selected from hydrogen, C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, hydroxy, cyano, nitro, benzyl, -C(O)NR c R d 、-C(O)R c 、-C(O)OR c 、-OR c 、-OC(O)R c 、-OC(O)OR c 、-OC(O)NR c R d 、-NR c R d 、-SR c 、-S(O)R c 、-S(O) 2 R c or a 3-10 membered cycloalkyl, heterocyclyl, aryl or heteroaryl group containing 0-3 heteroatoms, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl or benzyl group is unsubstituted or optionally substituted with 1-3 R c replace; Each R c , R d are independently selected from hydrogen, halogen, carbonyl, hydroxyl, cyano, nitro, phenyl, benzyl, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, halogenated C 1 -C 6 Alkoxy, C 3 -C 6 Cycloalkyl or halogenated C 3 -C 6 Cycloalkyl; m, n, and p are independently selected from 0, 1, 2 or 3.

2. The compound according to claim 1, which has a structure of Formula Ia, Formula Ib or Formula Ic: in, X, Y, Z, m, n, and p are as defined in Formula I.

3. The compound according to claim 1 or 2, Features: X is selected from -OH, -NH 2 or -OCH 3 .

4. The compound according to claim 1, Features: R 2 Selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 Alkynyl, halogen, cyano, nitro, -C(O)NR a R b 、-C(O)R a 、-C(O)OR a 、-OR a 、-OC(O)R a 、-OC(O)OR a 、-OC(O)NR a R b 、-NR a R b 、-SR a 、-S(O)R a 、-S(O) 2 R a ; R a , R b are independently selected from hydrogen, C 1 -C 6 Alkyl or -C(O)R c ; R c Selected from hydrogen, halogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 1 -C 6 Alkoxy, halogenated C 1 -C 6 Alkoxy or C 3 -C 6 Cycloalkyl; Ring Y is selected from C 6 -C 12 Aryl or 5-10 membered heteroaryl.

5. The compound according to claim 4, Features: R 3 Selected from hydrogen, C 1 -C 6 Alkyl, halogenated C 1 -C 6 Alkyl, C 2 -C 6 Alkenyl, C 2 -C 6 alkynyl, halogen, cyano or nitro; R 4 Selected from hydrogen, deuterium, halogen or C 1 -C 6 alkyl; R 5 Selected from hydrogen, deuterium or C 1 -C 12 alkyl; m and n are independently selected from 1; p is selected from 0 or 1.

6. The compound according to claim 1, Features Selected from:

7. A pharmaceutical composition, It is characterized in that A therapeutically effective amount of a compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt, tautomer, mesoform, racemate, enantiomer, diastereomer thereof, and a pharmaceutically acceptable carrier or excipient.

8. Use of the compound according to any one of claims 1 to 6 in the preparation of a medicament for treating or preventing diseases associated with GSPT1, IKZF1, IKZF2, IKZF3, CK1α, N-MYC or C-MYC protein mutations, expression imbalances, conformational changes and functional abnormalities.

9. The use according to claim 8, It is characterized in that The related diseases are cancer, viral infection, aging, immune diseases, and neurological diseases; wherein the cancer is selected from acute myeloid leukemia, liver cancer, acute lymphocytic leukemia, bladder cancer, bone cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, chronic lymphocytic leukemia CLL, chronic myeloid leukemia CML, colon cancer, esophageal cancer, gallbladder cancer, gastric cancer, gastrointestinal stromal tumors, head and neck cancer, Hodgkin's lymphoma, laryngeal cancer, leukemia, lung cancer, melanoma, mesothelioma, multiple myeloma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, kidney cancer, sarcoma, skin cancer, small cell lung cancer, testicular cancer, pharyngeal cancer, thyroid cancer or uterine cancer.

10. Use of the compound according to any one of claims 1 to 6 in the preparation of a GSPT1 degrading agent.

Citation Information

Patent Citations

  • Degradation agent capable of simultaneously targeting BTK and GSPT1 proteins

    CN115304606A

  • Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons

    WO2022200857A1

  • Ketoamides for treating malignancy

    WO2023070120A1

Cited By

  • A process for the preparation of 2-hydroxy-3-(3-bromophenyl) acrylic acid

    CN122705412A